Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 5
1952 1
1953 1
1954 1
1955 1
1956 7
1957 5
1958 2
1959 4
1960 2
1961 13
1962 4
1963 6
1964 3
1965 3
1966 12
1967 12
1968 9
1969 17
1970 4
1971 14
1972 14
1973 19
1974 12
1975 22
1976 18
1977 23
1978 26
1979 25
1980 38
1981 32
1982 48
1983 51
1984 33
1985 47
1986 53
1987 69
1988 66
1989 57
1990 54
1991 52
1992 56
1993 59
1994 61
1995 65
1996 82
1997 67
1998 63
1999 51
2000 73
2001 66
2002 65
2003 66
2004 63
2005 83
2006 56
2007 62
2008 46
2009 50
2010 56
2011 67
2012 80
2013 93
2014 118
2015 111
2016 98
2017 123
2018 116
2019 141
2020 137
2021 143
2022 161
2023 150
2024 39

Text availability

Article attribute

Article type

Publication date

Search Results

3,405 results

Results by year

Filters applied: . Clear all
Page 1
Integrated proteomics identifies p62-dependent selective autophagy of the supramolecular vault complex.
Kurusu R, Fujimoto Y, Morishita H, Noshiro D, Takada S, Yamano K, Tanaka H, Arai R, Kageyama S, Funakoshi T, Komatsu-Hirota S, Taka H, Kazuno S, Miura Y, Koike M, Wakai T, Waguri S, Noda NN, Komatsu M. Kurusu R, et al. Among authors: miura y. Dev Cell. 2023 Jul 10;58(13):1189-1205.e11. doi: 10.1016/j.devcel.2023.04.015. Epub 2023 May 15. Dev Cell. 2023. PMID: 37192622
Aging-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events.
Tsukamoto H, Komohara Y, Tomita Y, Miura Y, Motoshima T, Imamura K, Kimura T, Ikeda T, Fujiwara Y, Yano H, Kamba T, Sakagami T, Oshiumi H. Tsukamoto H, et al. Among authors: miura y. Proc Natl Acad Sci U S A. 2022 Jul 19;119(29):e2205378119. doi: 10.1073/pnas.2205378119. Epub 2022 Jul 11. Proc Natl Acad Sci U S A. 2022. PMID: 35858347 Free PMC article.
Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping.
Gee P, Lung MSY, Okuzaki Y, Sasakawa N, Iguchi T, Makita Y, Hozumi H, Miura Y, Yang LF, Iwasaki M, Wang XH, Waller MA, Shirai N, Abe YO, Fujita Y, Watanabe K, Kagita A, Iwabuchi KA, Yasuda M, Xu H, Noda T, Komano J, Sakurai H, Inukai N, Hotta A. Gee P, et al. Among authors: miura y. Nat Commun. 2020 Mar 13;11(1):1334. doi: 10.1038/s41467-020-14957-y. Nat Commun. 2020. PMID: 32170079 Free PMC article.
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T; AJM300 Study Group. Matsuoka K, et al. Among authors: miura y. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):648-657. doi: 10.1016/S2468-1253(22)00022-X. Epub 2022 Mar 30. Lancet Gastroenterol Hepatol. 2022. PMID: 35366419 Clinical Trial.
3,405 results